Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2016

Open Access 01-11-2016 | Original Article

Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target

Authors: Ling Ye, Sheng-tao Lin, Yu-shuai Mi, Yuan Liu, Yang Ma, Hui-min Sun, Zhi-hai Peng, Jun-wei Fan

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

This study investigated the significance of La-related protein 1 (LARP1) in the development and progression of colorectal cancer (CRC). Quantitative real-time polymerase chain reaction and Western blot analyses were carried out to determine the mRNA and protein expression of LARP1 in CRC tumor tissues and paired adjacent normal mucosa. The expression of LARP1 was upregulated in CRC. Immunohistochemical analysis using tissue microarray was performed. A positive correlation between LARP1 and proliferating cell nuclear antigen (PCNA) in the area of proliferation was observed using the Spearman’s correlation coefficient test (r = 0.332, P < 0.01). The elevated expression of LARP1 significantly correlated with T stage (P = 0.02), N stage (P = 0.006), M stage (P < 0.001), American Joint Committee on Cancer (AJCC) stage (P = 0.04), differentiation rank (P < 0.001), and PCNA level (P < 0.001). In addition, the inhibitory effect of LARP1 knockdown on CRC cell proliferation was demonstrated using Cell Counting Kit-8 (CCK8) and colony-forming cell (CFC) assays. Multivariate analysis showed that LARP1 was an independent prognostic factor for overall survival (OS; hazard rate (HR) = 0.244; 95 % confidence interval (CI), 0.078–0.769; P = 0.016) and disease-free survival (DFS; HR = 0.281; 95 % CI, 0.086–0.917; P = 0.035) in CRC patients. LARP1 plays an important role in the proliferation of colorectal cancer and represents a new prognostic indicator.
Literature
1.
2.
3.
4.
Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol. 2013;8(2):83–96.CrossRefPubMed
5.
6.
Akkad J, Bochum S, Martens UM. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. Langenbeck’s Arch Surg. 2015;400(2):129–43.CrossRef
7.
Fan J et al. Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genome wide gene-expression analyses: identification and validation of IFITM3 as a biomarker of early colon carcinogenesis. Cancer. 2008;113(2):266–75.CrossRefPubMed
8.
9.
10.
Liu D et al. Activation of mammalian target of rapamycin pathway confers adverse outcome in non small cell lung carcinoma. Cancer. 2011;117(16):3763–73.CrossRefPubMed
11.
12.
Lee HW, Lee EH, et al. Prognostic significance of phosphorylated 4E-binding protein 1 in non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(4):3955–62.
13.
Castello A et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012;149(6):1393–406.CrossRefPubMed
14.
Mura M et al. LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene. 2015;34(39):5025–36.CrossRefPubMed
15.
Deragon J-M, Bousquet-Antonelli C. The role of LARP1 in translation and beyond. Wiley Interdisciplinary Reviews: RNA. 2015;6(4):399–417.
16.
17.
Aoki K et al. LARP1 specifically recognizes the 3′ terminus of poly(a) mRNA. FEBS Lett. 2013;587(14):2173–8.CrossRefPubMed
18.
19.
Tcherkezian J et al. Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5’TOP mRNA translation. Genes Dev. 2014;28(4):357–71.CrossRefPubMedPubMedCentral
20.
Elias JM. Cell proliferation indexed a biomarker in solid tumors. Biotechnic & Histochemistry. 1996;72(2):78–85.CrossRef
21.
Guzinska-Ustymowicz K et al. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res. 2009;29:3049–52.
22.
Stoimenov I, Helleday T. PCNA on the crossroad of cancer. Biochem Soc Trans. 2009;37(Pt 3):605–13.CrossRefPubMed
23.
Zhang Z et al. Structure of monoubiquitinated PCNA: implications for DNA polymerase switching and Okazaki fragment maturation. Cell Cycle. 2012;11(11):2128–36.CrossRefPubMedPubMedCentral
24.
Sophie Chauvet CM-Z et al. dlarp a new candidate Hox target in drosophila whose orthologue in mouse is expressed at sites of epithelium mesenchymal interactions. Dev Dyn. 2000;218:401–13.CrossRef
25.
Ichihara K, Shimizu H, Taguchi O, et al. A Drosophila orthologue of larp protein family is required for multiple processes in male meiosis. Cell Struct Funct. 2007;32:89–100.CrossRefPubMed
26.
Blagden SP et al. Drosophila LARP associates with poly(a)-binding protein and is required for male fertility and syncytial embryo development. Dev Biol. 2009;334(1):186–97.CrossRefPubMed
27.
28.
Kato M et al. MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. Int J Oncol. 2015;47(2):710–8.PubMed
29.
Kato K et al. Expression form of p53 and PCNA at the invasive front in oral squamous cell carcinoma: correlation with clinicopathological features and prognosis. J Oral Pathol Med. 2011;40(9):693–8.CrossRefPubMed
30.
Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(20):3589–94.
Metadata
Title
Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target
Authors
Ling Ye
Sheng-tao Lin
Yu-shuai Mi
Yuan Liu
Yang Ma
Hui-min Sun
Zhi-hai Peng
Jun-wei Fan
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5332-3

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue

Original Article

Aberrant microRNA expression in tumor mycosis fungoides

Original Article

The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma

Review

Dysregulation of TTP and HuR plays an important role in cancers

Original Article

Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity

Original Article

IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo

Review

Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits